Preferred Label : Cotsiranib;
NCIt definition : A polypeptide nanoparticle (PNP)-based small interfering RNA (siRNA) therapeutic directed
against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2),
with potential antineoplastic activity. Upon intralesional administration, cotsiranib
binds to both TGF-beta 1 and COX-2 messenger RNAs (mRNAs), preventing the translation
and expression of TGF-beta 1 and COX-2 proteins. This inhibits TGF-beta 1-mediated
signaling and abrogates TGF-beta 1-mediated immunosuppression, which may enhance anti-tumor
immunity in the tumor microenvironment (TME) and promote a cytotoxic T-lymphocyte
(CTL)-mediated immune response against tumor cells leading to tumor cell death. The
inhibition of COX-2 prevents COX-2-mediated signaling, which may result in apoptosis
and a reduction in tumor cell proliferation, tumor angiogenesis and metastasis.;
Molecule name : STP 705; STP-705;
NCI Metathesaurus CUI : CL1413146;
Origin ID : C175941;
UMLS CUI : C5446869;
Semantic type(s)
- concept_is_in_subset
